Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Conventional Asthma Therapy · 1 trial · 1 indication
AEs were defined as undesirable medical conditions or deteriorations of a pre-existing medical condition following/during exposure. All Serious AEs, AEs leading to withdrawal, Other relevant AE were recorded.
| Arm | Type | Description |
|---|---|---|
| BUD - Budesonide | EXPERIMENTAL | Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily |
| CONV - Conventional Asthma Therapy | ACTIVE_COMPARATOR | Conventional Asthma Therapy - according to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator. |
| Name | Type | Description |
|---|---|---|
| Budesonide | DRUG | Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily |
| Conventional Asthma Therapy | DRUG | According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator. |
Inclusion Criteria: * Patient who complete preceding the Phase III study and provide a signed written informed consent by patient's legal representative at Visit 1 or 4 weeks prior to Visit 1 of the study. A signed written informed assent should also be obtained from the patients themselves as much...
Conventional Asthma Therapy is used for the treatment of asthma. It is being developed by AstraZeneca PLC as a small molecule therapy for respiratory conditions. The therapy is currently in Phase 3 clinical development, with one completed trial in Japanese children with bronchial asthma.
Conventional Asthma Therapy is developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The company is conducting clinical trials to evaluate the therapy's safety and efficacy in patients with asthma.
Conventional Asthma Therapy is in Phase 3 clinical development. It is an investigational therapy, meaning it has not yet been approved by regulatory authorities. One Phase 3 trial has been completed, and the therapy is still undergoing clinical evaluation for the treatment of asthma.
Conventional Asthma Therapy has one completed clinical trial, NCT00509028, titled 'Safety and Efficacy Study of Budesonide (Pulmicort®) Turbuhaler® in Japanese Children With Bronchial Asthma.' This Phase 3 trial enrolled 241 participants with asthma in Japan and was completed.
Conventional Asthma Therapy is associated with the drug budesonide, as indicated by the clinical trial NCT00509028, which studied budesonide (Pulmicort®) Turbuhaler®. The therapy is being developed by AstraZeneca PLC for the treatment of asthma.